Kite, A Gilead Company $GILD
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS9
PHASE 3 / 2-36
RECRUITING0
READOUTS ≤12 MONTHS2
READOUT SLIPPED >6 MO50%
Delay Index: of 6 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +30.0 months). See all sponsors →
Open Kite, A Gilead Company on the live radar map → 📅 $GILD readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| iMMagine-1 NCT05396885 |
P2 | Active, not recruiting | Multiple Myeloma | 136 | 2026-12 (+30 mo) |
| JKART-1 NCT06253663 |
P2 | Active, not recruiting | Relapsed/Refractory Mantle Cell Lymphoma; Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | 25 | 2027-07 (+2 mo) |
| iMMagine-3 NCT06413498 |
P3 | Active, not recruiting | Multiple Myeloma | 452 | 2028-07 |
| PALISADES-1 NCT04989803 |
P1/2 | Active, not recruiting | Relapsed and/or Refractory B-cell Lymphoma | 247 | 2030-02 (+49 mo) |
| ZUMA-22 NCT05371093 |
P3 | Active, not recruiting | Relapsed/Refractory Follicular Lymphoma | 231 | 2030-10 (+42 mo) |
| ZUMA-23 NCT05605899 |
P3 | Active, not recruiting | High-risk Large B-cell Lymphoma (LBCL) | 300 | 2031-03 |
| KITE-753 NCT07479797 |
P3 | Active, not recruiting | Relapsed or Refractory Large B-cell Lymphoma | 550 | 2031-05 |
| iMMagine-6 NCT07903506 |
P3 | Not yet recruiting | Newly Diagnosed Multiple Myeloma | 750 | 2039-03 |
| iMMagine-4 NCT07887672 |
P3 | Not yet recruiting | Newly Diagnosed Multiple Myeloma | 600 | 2042-02 |